Department of Pathology, University of Helsinki, Helsinki, Finland.
Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Biopreserv Biobank. 2020 Aug;18(4):337-345. doi: 10.1089/bio.2020.0021. Epub 2020 Jun 16.
Archived formalin-fixed paraffin-embedded (FFPE) specimens from nonmalignant tissues derived from cancer patients are a vast and potentially valuable resource for high-quality genotyping analyses and could have a role in establishing inherited cancer risk. We systematically searched PubMed, Ovid MEDLINE, and Scopus databases for all articles that compared genotyping performance of DNA from nonmalignant FFPE tissue with blood DNA derived from cancer patients irrespective of tumor type. Two independent researchers screened the retrieved studies, removed duplicates, excluded irrelevant studies, and extracted genotyping data from the eligible studies. These studies included, but were not limited to, genotyping technique, reported call rate, and concordance. Thirteen studies were reviewed, in which DNA from nonmalignant FFPE tissues derived from cancer patients was successfully purified and genotyped. All these studies used different approaches for genotyping of DNA from nonmalignant FFPE tissues to amplify single nucleotide polymorphisms (SNPs) and to estimate of loss of heterozygosity. The concordance between genotypes from nonmalignant FFPE tissues and blood derived from cancer patients was observed to be high, whereas the call rate of the tested SNPs was not reported in all included studies. This review illustrates that DNA from nonmalignant FFPE tissues derived from cancer patients can serve as an alternative and reliable source for assessment of germline DNA for various purposes, including assessment of cancer predisposition.
存档的福尔马林固定石蜡包埋(FFPE)非恶性组织标本来源于癌症患者,是高质量基因分型分析的巨大且潜在有价值的资源,并且可能在确定遗传性癌症风险方面发挥作用。我们系统地检索了 PubMed、Ovid MEDLINE 和 Scopus 数据库,以获取所有比较源自癌症患者的非恶性 FFPE 组织与血液 DNA 的基因分型性能的文章,无论肿瘤类型如何。两名独立的研究人员筛选了检索到的研究,去除重复项,排除不相关的研究,并从合格的研究中提取基因分型数据。这些研究包括但不限于基因分型技术、报告的检出率和一致性。有 13 项研究被审查,这些研究成功地从癌症患者的非恶性 FFPE 组织中纯化和基因分型 DNA。所有这些研究都使用不同的方法来对非恶性 FFPE 组织中的 DNA 进行基因分型,以扩增单核苷酸多态性(SNP)并估计杂合性丢失。观察到源自癌症患者的非恶性 FFPE 组织的基因型与源自癌症患者的血液之间的一致性很高,而在所有纳入的研究中均未报告所测试 SNP 的检出率。本综述表明,源自癌症患者的非恶性 FFPE 组织中的 DNA 可作为替代可靠的来源,用于评估各种目的的胚系 DNA,包括评估癌症易感性。